The human PTH radioimmunoassay has been developed by use of bovine PTH and anti-bovine PTH antiserum, both of which were commercially available. The iodination process was modified as to use acid solution resulting in the more stable 125I-PTH. However, the PTH radioimmunoassay employed this antiserum with 125I-bovine PTH revealed that the N-terminal portion of PTH molecule was reactive only slightly in this system, indicating that most of PTH determined by this radioimmunoassay might be an biologically inactive PTH.
Plasma from normal subjects and patients with primary hyperparathyroidism or uremia showed dilutional curves parallel to the curve of the standard bovine PTH, indicating the immunological identity between human and bovine PTH in this radioimmunoassay system. The extract from the parathyroid adenoma showed an identical dilutional curve, but the extract from the ectopic PTH producing tumor showed a different dilutional curve from that of the standard PTH, which might indicate the immunochemical heterogeneity of PTH produced from the ectopic source. Plasma PTH levels obtained from normal subjects and patients with primary hyperparathyroidism, uremia or pseudohypoparathyroidism were compatible with those reported previously. These data indicate that the human PTH radioimmunoassay can be done by use of commercially available anti-bovine PTH antiserum and bovine PTH in conjunction with the modified iodination process and double antibody method. However, this assay was directed mainly to the C-terminal portion of PTH molecule and the PTH radioimmunoassay specific for the N-terminal portion will be required to evaluate the PTH regulation more precisely in man.
Since Berson et al. reported the radioimmunoassay of parathyroid hormone (PTH) in human plasma and tissue (Berson et al., 1963) , there have appeared several papers concerning the human PTH radioimmunoassay (Reiss and Canterbury, 1968; Schopman et al., 1970; Arnaud et al., 1971; Segre et al., 1972; Hori et al., 1972; Reity and Weinstein, 1973) . However, human PTH is hard to obtain even in small quantity to use for the iodination. Berson et al. used crude bovine PTH to produce antibodies in guinea pigs and the more purified bovine PTH for the iodination and the assay standard (Berson et al., 1963) . Most papers concerning the human PTH radioimmunoassay were employing bovine PTH as antigen for both the assay standard and the immunization, but Arnaud et al. used anti-porcine PTH antiserum, bovine PTH for the iodination and plasma from a patient with primary hyperparathyroidism for the assay standard ). Therefore, it was required to examine the specificity of each PTH radioimmunoassay system prior to determining plasma or tissue PTH levels in man.
Furthermore, it has become recognized that PTH in human plasma is immunoheterogenous and more than one immunoreactive species of PTH circulate in plasma (Arnaud et al., 1972) . Therefore, the PTH radioimmunoassay using different antiserum could produce different results.
These data indicate that each PTH radioimmunoassay system should be examined carefully what portion of PTH molecule is reacting with the antibody.
Recently, anti-bovine PTH antisera have become available commercially. By using this antiserum, we have developed the PTH radioimmunoassay in human plasma and tissue in conjunction with charactreizing the specificity of the antiserum. In addition, we have modified the iodination process of PTH and increased the protein concentration of the incubation mixture in order to keep PTH stable and to avoid the adsorption on glass-wares. The double antibody method was employed to separate the bound from the Here, we are reporting the human PTH radioimmunoassay using bovine PTH and anti-bovine PTH antiserum, both of which are commercially available, with the modified proccess of iodination.
Materials and Methods
Highly purified bovine PTH was obtained from Wilson Laboratories, Park Forest South, Ill., U.S.A. Synthetic 1-34bovine PTH was obtained from Beckman Instruments, Inc., Palo Alto, Ca., U.S.A. Antibovine PTH antisera (211/41 and 211/32) were purchased from Wellcome Research Laboratories, Beckenham, England. Bovine or human albumin was the fraction V powder commercially available. QUSO was obtained from Philadelphia Quartz Co., Chester, Pa., U.S.A. 125I was obtained from the New England Nuclear, Boston, Mass., U.S.A., as a carrier free Na 12 5I. PTH free plasma was collected from patients with hypercalcemia due to generalized bone metastases.
Iodination of PTH
The method of iodination was based on that re- Preparation of incubation mixture The final incubation volume was 0.3 ml, which consisted of 0.1 m/ PTH free plasma containing PTH standard or 0.1 ml assay sample, 0.1 m/ 125I-PTH and 0.1 ml antiserum properly diluted with diluent buffer containing 1 % normal guinea pig plasma. The diluent buffer was 0.08 M Veronal buffer, pH 8.6, containing 2 % human albumin and 500 KIU/ml Trasylol. This diluent was used for diluting 125I-PTH . To prepare the standard PTH solution, plasma of a normal subject that had been absorbed with 2.5 % QUSO was employed. This plasma was compared with that of a patient with hypercalcemia due to bone metastases and both were proved to behave identically in the PTH radioimmunoassay system. Standard curve The standard curve using antiserum 211/41 diluted to 1: 90,000 showed that the trace B/T value was around 0.35, which was displaced by 5 ng bovine PTH to less than 0.05 (Fig. 1 ). Ten per cent fall level was observed at the standard PTH concentration of at least 0.015 ng in every assay, indicating that it was possible to detect plasma PTH concentration as low as 0.15 ng/ml. However, the standard curve using antiserum 211/32 diluted to 1: 160,000 was much less sensitive to that of 211/41 and it was possible to detect 0.5 ng of the standard PTH per tube.
Dose response and cross reaction
Dilutional curves of plasma from patients with uremia or primary hyperparathyroidism, tumor extracts from patients with parathyroid adenoma or the ectopic PTH syndrome, and synthetic 1-34bovine PTH were depicted in Figure 1 , when the antiserum 211/41 was employed. Plasma from patients with uremia or primary hyperparathyroidism and the extract from parathyroid adenoma showed the dilutional curve identical to that of the standard bovine PTH. However, the extract of the ectopic PTH producing tumor showed the different dilutional curve from that of the standard. Synthetic 1-34bovine PTH showed a slight cross reaction in this system, but the dose response curve was quite different from that of the standard PTH.
Plasma PTH levels in patients with various diseases Normal PTH levels measured by this radioimmunoassay were less than 0.5 ng/ml. Plasma PTH levels of patients with primary hyperparathyroidism were high at a range of 0.8-5.3 ng/ml. A patient with parathyroid carcinoma had a distinctly elevated plasma Fig. 1 Dilutional curves of the standard bovine PTH, synthetic 1-34bovine PTH, plasma from patients with primary hyperparathyroidism or uremia, and the tumor extracts from patients with parathyroid adenoma or pseudohyperparathyroidism, using antiserum 211/41 diluted to 1: 90,000.
PTH level of 11.3 ng/ml. Plasma PTH levels of patients with uremia ranged from 0.8 to 29.0 ng/ml. In patients with hypercalcemia due to bone metastases and a patient with primary hypoparathyroidism, plasma PTH levels were undetectable and less than 0.15 ng/ ml. In patients with the ectopic PTH syndrome (pseudohyperparathyroidism), plasma PTH levels were detectable in a range of 0.15-0.5 ng/ml even in the presence of marked hypercalcemia.
The extracts of parathyroid adenoma and carcinoma revealed the PTH content of 12.5 and 1.35 ,ug/g of wet tissue respectively. However, it has become recognized that human PTH is immunoheterogenous -that is, that more than one immunoreactive species of PTH are present (Berson and Yalow, 1968; Segre et al., 1972; Arnaud, 1973) . These observations indicate that plasma PTH values obtained by the radioimmunoassay are determined by what portion of PTH molecule reacts with the antibody used for
